Search

Your search keyword '"Doi, Yuko"' showing total 237 results
Start Over Author "Doi, Yuko"
237 results on '"Doi, Yuko"'

3. Enhanced efficacy of the novel recombinant clone VasSF in a mouse model of antineutrophil cytoplasmic antibody-associated vasculitis.

Author

Koura, Minako, Kameoka, Yosuke, Kishi, Fukuko, Yamakawa, Yoshio, Ito, Fuyu, Sugamata, Ryuichi, Doi, Yuko, Uno, Kazuko, Nakayama, Toshinori, Miki, Takashi, Nakajima, Hiroshi, Suzuki, Kazuo, and Suzuki, Osamu

Subjects
ANTINEUTROPHIL cytoplasmic antibodies, LABORATORY mice, MOLECULAR cloning, ANIMAL disease models, HIGH performance liquid chromatography
Abstract

Based on the efficacy of intravenous immunoglobulin (IVIg) for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), we developed a recombinant single-chain-fragment variable clone, VasSF, therapeutic against AAV in a mouse model (SCG/Kj mice). VasSF is thought to bind to vasculitis-associated apolipoprotein A-II (APOA2) as a target molecule. VasSF is a promising new drug against AAV, but difficulties in the yield and purification of VasSF remain unresolved. We produced monomers of new VasSF molecules by modifying the plasmid structure for VasSF expression and simplifying the purification method using high-performance liquid chromatography. We compared the therapeutic effects between 5-day continuous administration of the monomers, as in IVIg treatment, and single shots of 5-day-equivalent doses. We also evaluated the life-prolonging effect of the single-shot treatment. Two-dimensional western blots were used to examine the binding of VasSF to APOA2. Our improved manufacturing method resulted in a 100-fold higher yield of VasSF than in our previous study. Monomerization of VasSF stabilized its efficacy. Single shots of a small amount (1/80 000 of IVIg) produced sufficient therapeutic effects, including decreased glomerular crescent formation, a decreasing trend of serum ANCA against myeloperoxidase (MPO-ANCA), decreases in multiple proinflammatory cytokines, and a trend toward prolonged survival. Two-dimensional western blots confirmed the binding of VasSF to APOA2. The newly produced pure VasSF monomers are stable and therapeutic for AAV with a single low-dose injection, possibly by removing vasculitis-associated APOA2. Thus, the new VasSF described herein is a promising drug against AAV. AAV is believed to develop with ANCA production after a cytokine storm caused by microbe infection. Here, we produced completely pure and stable monomers of VasSF and then demonstrated its efficacy with a single shot of a small amount: decreased glomerular crescent formation, MPO-ANCA, and proinflammatory cytokines. In addition, the VasSF-treated group tended to survive longer than the control group. Two-dimensional western blots confirmed the binding of VasSF to APOA2 (aberrant APOA2: aberrant HDL), indicating that VasSF would be a promising drug against AAV. Graphical Abstract [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group

Author

Itonaga, Hidehiro, Tsushima, Hideki, Imanishi, Daisuke, Hata, Tomoko, Doi, Yuko, Mori, Sayaka, Sasaki, Daisuke, Hasegawa, Hiroo, Matsuo, Emi, Nakashima, Jun, Kato, Takeharu, Horai, Makiko, Taguchi, Masataka, Matsuo, Masatoshi, Taniguchi, Hiroaki, Makiyama, Junnya, Sato, Shinya, Horio, Kensuke, Ando, Koji, Moriwaki, Yuji, Sawayama, Yasushi, Ogawa, Daisuke, Yamasaki, Reishi, Takasaki, Yumi, Imaizumi, Yoshitaka, Taguchi, Jun, Kawaguchi, Yasuhisa, Yoshida, Shinichiro, Joh, Tatsuro, Moriuchi, Yukiyoshi, Nonaka, Hiroaki, Soda, Hisashi, Fukushima, Takuya, Nagai, Kazuhiro, Kamihira, Shimeru, Tomonaga, Masao, Yanagihara, Katsunori, and Miyazaki, Yasushi

Published
2014
Full Text
View/download PDF

7. Trends in Prescribing Antipsychotics for Children and Adolescents in Japan: A Descriptive Epidemiological Study Using a Large-Scale Pharmacy Dataset.

Author

Nakane, Sayuri, Tanaka-Mizuno, Sachiko, Nishiyama, Chika, Kochi, Kenji, Yamamoto-Sasaki, Madoka, Takeuchi, Masato, Ogawa, Yusuke, Doi, Yuko, Arai, Masaru, Fujii, Yosuke, Matsunaga, Toshiyuki, Furukawa, Toshiaki A., and Kawakami, Koji

Subjects
CONCOMITANT drugs, ANTIPSYCHOTIC agents, PHARMACY, TEENAGERS, PSYCHIATRIC drugs
Abstract

Little is known about antipsychotic prescription patterns among children and adolescents in Japan, particularly in outpatient settings. We investigated the prevalence and trends of antipsychotic prescription for outpatients aged ≤ 17 years receiving a first antipsychotic prescription from 2006 to 2012 based on a large-scale dispensation dataset. Measurements included age, sex, department of diagnosis and treatment, type of prescription (monotherapy or polytherapy), antipsychotic dosage, and concomitant psychotropic drugs. Of the 10,511 patients, 65.1% were aged 13–17 years, and 52.9% were males. Second-generation antipsychotic monotherapy prescriptions increased from 53.8% in 2006 to 78.3% in 2012. Risperidone was the most frequently prescribed antipsychotic, followed by aripiprazole and olanzapine. Approximately 25.0% of patients were prescribed an initial dose less than recommended. Second-generation antipsychotic monotherapy is currently the most frequent prescription pattern among outpatients aged ≤ 17 years receiving an initial antipsychotic prescription. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group

Author

Itonaga, Hidehiro, Tsushima, Hideki, Imanishi, Daisuke, Hata, Tomoko, Doi, Yuko, Mori, Sayaka, Sasaki, Daisuke, Hasegawa, Hiroo, Matsuo, Emi, Nakashima, Jun, Kato, Takeharu, Horai, Makiko, Taguchi, Masataka, Matsuo, Masatoshi, Taniguchi, Hiroaki, Makiyama, Junnya, Sato, Shinya, Horio, Kensuke, Ando, Koji, Moriwaki, Yuji, Sawayama, Yasushi, Ogawa, Daisuke, Yamasaki, Reishi, Takasaki, Yumi, Imaizumi, Yoshitaka, Taguchi, Jun, Kawaguchi, Yasuhisa, Yoshida, Shinichiro, Joh, Tatsuro, Moriuchi, Yukiyoshi, Nonaka, Hiroaki, Soda, Hisashi, Fukushima, Takuya, Nagai, Kazuhiro, Kamihira, Shimeru, Tomonaga, Masao, Yanagihara, Katsunori, Miyazaki, Yasushi, Itonaga, Hidehiro, Tsushima, Hideki, Imanishi, Daisuke, Hata, Tomoko, Doi, Yuko, Mori, Sayaka, Sasaki, Daisuke, Hasegawa, Hiroo, Matsuo, Emi, Nakashima, Jun, Kato, Takeharu, Horai, Makiko, Taguchi, Masataka, Matsuo, Masatoshi, Taniguchi, Hiroaki, Makiyama, Junnya, Sato, Shinya, Horio, Kensuke, Ando, Koji, Moriwaki, Yuji, Sawayama, Yasushi, Ogawa, Daisuke, Yamasaki, Reishi, Takasaki, Yumi, Imaizumi, Yoshitaka, Taguchi, Jun, Kawaguchi, Yasuhisa, Yoshida, Shinichiro, Joh, Tatsuro, Moriuchi, Yukiyoshi, Nonaka, Hiroaki, Soda, Hisashi, Fukushima, Takuya, Nagai, Kazuhiro, Kamihira, Shimeru, Tomonaga, Masao, Yanagihara, Katsunori, and Miyazaki, Yasushi

Abstract

An appropriate trigger for BCR-ABL1 mutation analysis has not yet been established in unselected cohorts of chronic-phase chronic myelogenous leukemia patients. We examined 92 patients after 12 months of tyrosine kinase inhibitor (TKI) treatment in Nagasaki Prefecture, Japan. Univariate analysis revealed that significant factors associated with not attaining a major molecular response (MMR) were the presence of the minor BCR-ABL1 fusion gene, a low daily dose of TKI, and the emergence of BCR-ABL1 kinase domain mutations conferring resistance to imatinib. Factors associated with the loss of sustained MMR were a low daily dose of TKI and the emergence of alternatively spliced BCR-ABL1 mRNA with a 35-nucleotide insertion. Taken together, our results suggest that the search for BCR-ABL1 mutations should be initiated if patients have not achieved MMR following 12 months of TKI treatment., identifier:Leukemia Research, 38(1), pp.76-83; 2014

Published
2020

38. Effects of administering different vehicles via single intratracheal instillation on responses in the lung and pleural cavity of Crl:CD(SD) rats

Author

Numano, Takamasa, primary, Morioka, Mai, additional, Higuchi, Hitomi, additional, Uda, Kazunari, additional, Sugiyama, Taiki, additional, Hagiwara, Teruaki, additional, Doi, Yuko, additional, Imai, Norio, additional, Kawabe, Mayumi, additional, Mera, Yukinori, additional, and Tamano, Seiko, additional

Published
2020
Full Text
View/download PDF

41. High Human T Cell Leukemia Virus Type-1(HTLV-1) Provirus Load in Patients with HTLV-1 Carriers Complicated with HTLV-1-unrelated disorders

Author

Yamada Yasuaki, Iwanaga Masako, Tsukasaki Kunihiro, Yanagihara Katsunori, Hasegawa Hiroo, Doi Yuko, Sasaki Daisuke, Watanabe Toshiki, and Kamihira Shimeru

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background To address the clinical and virological significance of a high HTLV-1 proviral load (VL) in practical blood samples from asymptomatic and symptomatic carriers, we simultaneously examined VL and clonal expansion status using polymerase chain reaction (PCR) quantification (infected cell % of peripheral mononuclear cells) and Southern blotting hybridization (SBH) methods. Results The present study disclosed extremely high VL with highly dense smears with or without oligoclonal bands in SBH. A high VL of 10% or more was observed in 16 (43.2%) of a total of 33 samples (one of 13 asymptomatic carriers, 8 of 12 symptomatic carriers, and 7 of 8 patients with lymphoma-type ATL without circulating ATL cells). In particular, an extremely high VL of 50% or more was limited to symptomatic carriers whose band findings always contained at least dense smears derived from polyclonally expanded cells infected with HTLV-1. Sequential samples revealed that the VL value was synchronized with the presence or absence of dense smears, and declined at the same time as disappearing dense smears. Dense smears transiently emerged at the active stage of the underlying disease. After disappearance of the smears, several clonal bands became visible and were persistently retained, explaining the process by which the clonality of HTLV-1-infected cells is established. The cases with only oligoclonal bands tended to maintain a stable VL of around 20% for a long time. Two of such cases developed ATL 4 and 3.5 years later, suggesting that a high VL with oligoclonal bands may be a predisposing risk to ATL. Conclusion The main contributor to extremely high VL seems to be transient emergence of dense smears detected by the sensitivity level of SBH, corresponding to polyclonal expansion of HTLV-1-infected cells including abundant small clones. Major clones retained after disappearance of dense smears stably persist and acquire various malignant characteristics step by step.

Published
2010
Full Text
View/download PDF

43. Promotion of liver and kidney carcinogenesis by ethyl tertiary-butyl ether (ETBE) in male Wistar rats

Author

Hagiwara, Akihiro, Doi, Yuko, Imai, Norio, Suguro, Mayuko, Kawabe, Mayumi, Furukawa, Fumio, Tamano, Seiko, Nagano, Kasuke, and Fukushima, Shoji

Subjects
N-ethyl-N-(2-hydroxyethyl)nitrosamine, hepatic carcinogenesis, renal carcinogenesis, tumor promotion, Original Article, Wistar rat, ethyl tertiary-butyl ether
Abstract

Tumor-promoting effects of ethyl tertiary-butyl ether (ETBE) were investigated in a 2-stage carcinogenesis bioassay with regard to hepatic and renal carcinogenesis in rats. Male 6-week-old Wistar rats were given drinking water containing N-ethyl-N-(2-hydroxyethyl)nitrosamine (EHEN), as an initiator, at a dose of 500 ppm for 2 weeks. Starting one week thereafter, the animals were administered ETBE at dose levels of 0 (control), 100, 300, 500 or 1,000 mg/kg/day by gavage for 19 weeks from week 4 to 22. Necropsy of all rats was performed at week 23, and livers and kidneys were examined histopathologically. Incidences of hepatocellular adenomas, and those of combined hepatocellular adenomas and carcinomas were significantly elevated in rats given 1,000 mg/kg/day ETBE, but not 100‒500 mg/kg/day ETBE, and there was a significant increase in the average numbers of lesions. No significant differences in incidences and average numbers of renal tubule neoplasms were found in rats administered 100‒1,000 mg/kg/day ETBE. However, the average numbers of atypical tubule hyperplasias, considered to be preneoplastic lesions, were significantly increased in rats given ETBE at 1,000 mg/kg/day, but not in rats given 500 mg/kg/day or lower doses. Thus, these results imply that ETBE has hepatic and renal tumor-promoting activities that affect EHEN-induced carcinogenesis in male rats, and the no-observed-effect level is 500 mg/kg/day under the present experimental conditions.

Published
2015

47. No Promoting Effect of Ethyl Tertiary-butyl Ether (ETBE) on Rat Urinary Bladder Carcinogenesis Initiated with N-Butyl-N-(4-hydroxybutyl)nitrosamine

Author

Hagiwara, Akihiro, Imai, Norio, Doi, Yuko, Suguro, Mayuko, Kawabe, Mayumi, Furukawa, Fumio, Nagano, Kasuke, and Fukushima, Shoji

Subjects
initiation/promotion, papillomatosis, F344 rats, Original Article, ETBE, urinary bladder carcinogenesis, soft stone
Abstract

The effects of ethyl tertiary-butyl ether (ETBE) on two-stage urinary bladder carcinogenesis in male F344 rats initiated with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) were investigated at various dose levels with regard to possible promoting activity. Groups of 30 rats were given drinking water containing 500 ppm BBN, as an initiator, for 4 weeks and starting one week thereafter received ETBE by gavage (daily, 7 days/week) at dose levels of 0 (control), 100, 300, 500 or 1000 mg/kg/day until experimental week 36. No statistically significant differences in incidences of preneoplastic lesions, papillomas, and carcinomas of the urinary bladder were evident in rats treated with 100-1000 mg/kg/day ETBE as compared with control values. Furthermore, the average numbers of preneoplastic or neoplastic lesions per unit length of basement membrane in rats given 100-1000 mg/kg/day ETBE were also comparable to control values. However, papillomatosis of the urinary bladder was found in 4 out of 30 rats (13%) in the group given 1000 mg/kg/day ETBE, and soft stones in the urinary bladder were found in 3 out of these 4 rats. The results thus demonstrated that ETBE did not exert promotional activity on urinary bladder carcinogenesis. However, papillomatosis of the urinary bladder developed in small numbers of the rats given ETBE at 1000 mg/kg/day but not in rats given 500 mg/kg/day or lower doses.

Published
2013

48. Conductive metal nanowires templated by the nucleoprotein filaments, complex of DNA and RecA protein

Author

Nishinaka, Taro, Takano, Atsushi, Doi, Yuko, Hashimoto, Makiko, Nakamura, Akira, Matsushita, Yushu, Kumaki, Jiro, and Yashima, Eiji

Subjects
Gold -- Chemical properties, Nucleoproteins -- Research, Chemistry
Abstract

The synthesis of conductive metal nanowire from nucleoprotein filaments, complexes of single- or double-stranded DNA and RecA protein is reported. A genetically engineered RecA derivative possessing a reactive and surface accessible cysteine residue reacted with funtionalized gold particles, resulting in nucleoprotein filaments with gold particles attached.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results